Literature DB >> 11866217

MR contrast agents in hepatic cirrhosis and chronic hepatitis.

Luis Martí-Bonmatí1.   

Abstract

Chronic liver disease alters the gross architecture of the liver and its arterial and portal blood supply. The relative proportion of regenerative hepatocytes, necrosis, extracellular interstitial space, and fibrosis is responsible for liver enhancement after the administration of a contrast agent. Because contrast agents can be directed toward either the extracellular or the intracellular spaces, knowledge of the different parenchymal enhancement alterations seen after the administration of these agents is necessary to understand how chronic liver disease pathologic changes influence contrast-enhanced magnetic resonance (MR) images. This article reviews the effect of chronic liver disease on MR contrast enhancement, as well as the effect of altered enhancement on lesion detection and characterization. Both extracellular and intracellular contrast agents are considered.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11866217     DOI: 10.1016/s0887-2171(02)90031-4

Source DB:  PubMed          Journal:  Semin Ultrasound CT MR        ISSN: 0887-2171            Impact factor:   1.875


  3 in total

Review 1.  Magnetic Resonance imaging analysis of liver fibrosis and inflammation: overwhelming gray zones restrict clinical use.

Authors:  D Marti-Aguado; A Rodríguez-Ortega; A Alberich-Bayarri; L Marti-Bonmati
Journal:  Abdom Radiol (NY)       Date:  2020-08-28

2.  Quantitative evaluation of hepatic fibrosis by fibro Scan and Gd-EOB-DTPA-enhanced T1 mapping magnetic resonance imaging in chronic hepatitis B.

Authors:  Qingtao Li; Tianyou Chen; Nannan Shi; Wen Ye; Min Yuan; Yuxin Shi
Journal:  Abdom Radiol (NY)       Date:  2021-11-25

3.  MR imaging in liver cirrhosis: classical and new approaches.

Authors:  Luis Martí-Bonmatí; Fructuoso Delgado
Journal:  Insights Imaging       Date:  2010-08-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.